^
    Back
    Association details:
    Biomarker:ZRANB1 overexpression
    Cancer:Prostate Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Commun
    Title:

    TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks

    Published date:
    03/31/2023
    Excerpt:
    Prostate cancer cells with TRABID overexpression exhibit a high sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors.
    DOI:
    10.1038/s41467-023-37499-5 Free PMC article